Literature DB >> 7242601

Effect of quinidine on digoxin concentration in skeletal muscle and serum in patients with atrial fibrillation. Evidence for reduced binding of digoxin in muscle.

K Schenck-Gustafsson, T Jogestrand, R Nordlander, R Dahlqvist.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7242601     DOI: 10.1056/NEJM198107233050407

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

Review 1.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 2.  Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: an appraisal of study methodology.

Authors:  E M Antman; J M Arnold; P L Friedman; T W Smith
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

3.  Influence of quinidine on the binding of [3H]-ouabain and [3H]-digoxin by human lymphocytes.

Authors:  K E Pedersen; N A Klitgaard
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  The quinidine-digoxin interaction in perspective.

Authors:  B Fichtl; W Doering
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 5.  Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations.

Authors:  A D Mooradian
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

6.  Skeletal muscle binding and renal excretion of digoxin in man.

Authors:  K Schenck-Gustafsson; T Jogestrand; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Quinidine-induced changes in serum and skeletal muscle digoxin concentration; evidence of saturable binding of digoxin to skeletal muscle.

Authors:  T Jogestrand; K Schenck-Gustafsson; R Nordlander; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.